Category

Smartkarma Newswire

Samsung Life Insurance (032830) Earnings: FY Operating Profit Hits 2.50 Trillion Won on 33.79 Trillion Won in Sales

By | Earnings Alerts
“`html

  • Samsung Life recorded an operating profit of 2.50 trillion won for the fiscal year.
  • The company achieved total sales amounting to 33.79 trillion won.
  • Market analysts issued 14 buy recommendations for Samsung Life.
  • There are 4 hold recommendations on the stock, with no sell recommendations reported.

“`


Samsung Life Insurance on Smartkarma

Analysts on Smartkarma are closely monitoring Samsung Life Insurance, with insights from Sanghyun Park and Douglas Kim shedding light on the company’s strategic moves. Sanghyun Park‘s bullish perspective focuses on the impact of Lee Jae-Yong’s recent appeal verdict on Samsung Life’s stock price. Park discusses the potential consequences of Samsung F&M burning treasury shares, affecting Samsung Life’s stake. The upcoming value-up announcement and the balance between dividends and buybacks contribute to the volatility forecasted for Samsung Electronics. By providing detailed analysis, Park aims to enhance market understanding surrounding Samsung Life Insurance.

On the other hand, Douglas Kim’s bearish viewpoint highlights considerations regarding Samsung Life Insurance‘s classification of its stake in Samsung Electronics as a long-term holding stock. Kim outlines the implications of such a decision, emphasizing the restrictions on selling Samsung Electronics stocks for an extended period. The potential impact on ownership stake structures within Samsung Group adds complexity to the strategic direction of Samsung Life Insurance. Through his research, Kim offers a cautionary outlook on the possible outcomes of this classification for investors in the insurance sector.


A look at Samsung Life Insurance Smart Scores

FactorScoreMagnitude
Value4
Dividend5
Growth4
Resilience3
Momentum4
OVERALL SMART SCORE4.0

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, Samsung Life Insurance shows a positive long-term outlook. With high scores in Dividend and Growth, investors may find the company attractive for potential returns. The strong Value score indicates that the company is priced attractively relative to its fundamentals. In terms of Momentum, Samsung Life Insurance is showing a positive trend, suggesting it is gaining investor interest. However, the Resilience score, although not as high as the others, still indicates a moderate level of stability.

As a company, Samsung Life Insurance provides insurance services, focusing on life and health insurance for customers in South Korea. With solid scores across various factors, including Dividend and Growth, Samsung Life Insurance may be well-positioned for sustained performance in the long run, making it a potential option for investors seeking stable returns in the insurance sector.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars

Abbott India (BOOT) Earnings: Q3 Net Income Surpasses Estimates with 16% Growth

By | Earnings Alerts
  • Abbott India‘s net income for the third quarter was 3.61 billion rupees, surpassing estimates of 3.3 billion rupees.
  • Year-over-year net income growth was 16%.
  • Revenue reached 16.1 billion rupees, exceeding the estimated revenue of 15.81 billion rupees and marking a 12% increase from the previous year.
  • Total costs were reported at 12 billion rupees, also up by 12% year-over-year.
  • Following the earnings release, Abbott India‘s shares increased by 2.9% to 26,892 rupees, with 13,209 shares traded.
  • Market analysts show a positive outlook with 4 buy ratings, no hold ratings, and 1 sell rating.

A look at Abbott India Smart Scores

FactorScoreMagnitude
Value2
Dividend5
Growth4
Resilience5
Momentum4
OVERALL SMART SCORE4.0

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Abbott India Limited’s long-term outlook appears promising based on Smartkarma Smart Scores, which evaluate various aspects of the company. With high scores in Dividend and Resilience, investors may find Abbott India to be a stable and rewarding option. The company’s strong dividend score indicates a consistent track record of distributing profits to shareholders, while its resilience score reflects the ability to withstand market volatility and economic downturns.

Furthermore, Abbott India‘s above-average scores in Growth and Momentum suggest potential for expansion and positive stock price performance in the foreseeable future. Despite a moderate score in Value, the company’s overall outlook, bolstered by its diverse range of pharmaceutical and medical products, remains favorable for investors seeking a reliable and growing investment opportunity.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars

UPM-Kymmene OYJ (UPM) Earnings: Dividend Per Share Falls Short, But Adjusted EBIT Beats Estimates

By | Earnings Alerts
  • UPM-Kymmene’s full-year dividend per share was €1.50, slightly below the estimated €1.52.
  • For the fourth quarter, the company’s adjusted EBIT was €418 million, surpassing the forecast of €344.8 million.
  • The adjusted EBIT margin for the fourth quarter was 15.9%.
  • Analyst recommendations include 17 buys, 5 holds, and 1 sell.

A look at UPM-Kymmene OYJ Smart Scores

FactorScoreMagnitude
Value4
Dividend4
Growth3
Resilience3
Momentum3
OVERALL SMART SCORE3.4

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

UPM-Kymmene Oyj, a company that specializes in manufacturing forest products, appears to have a solid long-term outlook based on the Smartkarma Smart Scores. The company scores well in Value and Dividend, indicating that it is considered attractive in terms of its valuation and dividend payouts. While its Growth, Resilience, and Momentum scores are slightly lower, they still show positive indicators for the company’s overall performance.

With a focus on magazine papers, newsprint, fine papers, and specialty papers, as well as a range of other products like self-adhesive labels and packaging papers, UPM-Kymmene Oyj has established itself in multiple countries. The company’s Wood Products division adds to its diversified portfolio by producing sawn products, plywood, and other building materials. Overall, UPM-Kymmene Oyj’s strong Value and Dividend scores, combined with its diverse product offerings, suggest a promising outlook for the company in the long term.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars

AAK (AAK) Earnings Surpass Expectations: 4Q Net Sales and Operating Profit Beat Estimates

By | Earnings Alerts
“`html

  • AAK’s net sales in Q4 reached SEK 11.73 billion, surpassing the estimated SEK 11.33 billion.
  • Earnings per share (EPS) were reported at SEK 3.57.
  • A dividend of SEK 5.00 per share was declared.
  • Operating profit totaled SEK 1.27 billion, slightly above the estimate of SEK 1.26 billion.
  • The CEO expressed a cautiously optimistic outlook for the upcoming year.
  • AAK aims to grow its volumes faster than the underlying market and enhance its positive impact.
  • Analyst recommendations for AAK include 8 buy ratings, 2 hold ratings, and 2 sell ratings.

“`


A look at AAK Smart Scores

FactorScoreMagnitude
Value2
Dividend2
Growth5
Resilience3
Momentum4
OVERALL SMART SCORE3.2

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

AAK AB, a company that specializes in manufacturing and selling specialty vegetable oils and fats, shows a promising long-term outlook according to Smartkarma Smart Scores. With a high Growth score of 5, AAK is positioned well for future expansion and development in its industry. This indicates a positive outlook for the company’s potential for increasing revenue and market share over time. Additionally, the company scores well in Momentum with a score of 4, suggesting strong upward trends that may contribute to its future success.

While AAK scores lower in Value and Dividend at 2, its Resilience score of 3 indicates a moderate ability to weather market challenges and maintain stability. Overall, with a mix of high Growth and Momentum scores combined with moderate resilience, AAK appears to have a positive trajectory for the long-term, positioning it well for potential future growth in its market sectors.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars

Bechtle AG (BC8) Earnings: Preliminary FY Revenue Hits €8B with EBT Margin at 5.5%

By | Earnings Alerts
“`html

  • Bechtle AG‘s preliminary revenue for the 2024 fiscal year is approximately €8 billion.
  • The preliminary earnings before taxes (EBT) stand at around €345 million.
  • Bechtle achieved a preliminary EBT margin of 5.5% for 2024.
  • Final, audited financial results for Bechtle’s 2024 fiscal year will be released on 14 March 2025.
  • Current analyst recommendations include 11 buy ratings, 6 hold ratings, and 2 sell ratings for Bechtle AG.

“`


A look at Bechtle AG Smart Scores

FactorScoreMagnitude
Value3
Dividend3
Growth4
Resilience4
Momentum3
OVERALL SMART SCORE3.4

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Bechtle AG, a company that specializes in retailing computer and office supplies, is poised for a positive long-term outlook according to Smartkarma Smart Scores. With a Growth score of 4 and a Resilience score of 4, Bechtle AG demonstrates strong potential for expansion and the ability to weather uncertainties. This indicates a promising future for the company in terms of advancing its market presence and adapting to changing business environments. Although the Value and Dividend scores stand at 3 each, the favorable Growth and Resilience scores suggest Bechtle AG‘s strategic positioning for sustained success in the long run.

Furthermore, despite a Momentum score of 3, Bechtle AG‘s overall outlook remains optimistic based on its solid performance in Growth and Resilience. The company’s diversified product range, which includes personal computers, peripherals, mobile devices, software, and office furniture, positions it well for future expansion and profitability. With a focus on market adaptability and product innovation, Bechtle AG appears well-equipped to capitalize on emerging opportunities and establish a strong competitive presence in the retail sector.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars

Largan Precision (3008) Earnings: January Sales Surge 10.6% to NT$4.95 Billion

By | Earnings Alerts
“`html

  • Largan’s sales for January reached NT$4.95 billion.
  • This sales figure represents a 10.6% increase compared to previous measurements.
  • Analysts are showing confidence in the company with 18 buy ratings.
  • The stock is noted to have 8 hold ratings and 0 sell ratings.

“`


A look at Largan Precision Smart Scores

FactorScoreMagnitude
Value3
Dividend3
Growth4
Resilience5
Momentum5
OVERALL SMART SCORE4.0

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on Smartkarma Smart Scores, Largan Precision shows a promising long-term outlook. With a strong Growth score of 4 and Resilience and Momentum scores of 5 each, the company appears well-positioned for future success. Largan Precision is known for manufacturing and marketing optical lens modules and optoelectronic components for various applications such as LCD projectors, digital cameras, and LEDs. This indicates a diverse product portfolio and a solid foundation for sustainable growth.

While Largan Precision scores a respectable 3 in both Value and Dividend categories, it is the high scores in Growth, Resilience, and Momentum that truly stand out. These scores suggest that the company has the potential to continue its growth trajectory and maintain stability in the face of market challenges. Investors looking for a company with strong growth prospects and resilience may find Largan Precision an appealing long-term investment option.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars

TotalEnergies (TTE) Earnings: Q4 Adjusted Net Income Surpasses Estimates Despite Revenue Decline

By | Earnings Alerts
“`html

  • TotalEnergies reported an adjusted net income of $4.41 billion for the fourth quarter, beating estimates of $4.26 billion but marking a 16% decline year-over-year.
  • Adjusted EBITDA for the quarter was $10.53 billion, slightly below the estimate of $10.66 billion, and down 10% year-over-year.
  • The company’s exploration and production adjusted net operating income was $2.31 billion, subtly surpassing the estimate of $2.27 billion, though down 18% compared to last year.
  • Integrated LNG adjusted net operating income came in at $1.43 billion, which was close to the estimate of $1.32 billion, maintaining almost steady performance with a 1.6% decline year-over-year.
  • Integrated power adjusted net operating income rose by 9.1% to $575 million, exceeding the estimate of $512.5 million.
  • Refining and chemicals adjusted net operating income fell significantly by 50% to $318 million, missing the estimate of $336.7 million.
  • Marketing and services adjusted net operating income stood out with an 18% increase to $362 million, surpassing the forecast of $309.1 million.
  • Net income was $3.96 billion, showing a 22% decline year-over-year, slightly below the estimate of $4.07 billion.
  • Adjusted earnings per share (EPS) were $1.90, slightly ahead of the estimate of $1.86, but down from $2.16 year-over-year.
  • Total revenues were reported at $47.12 billion, showing a 14% decrease year-over-year, just under the forecast of $47.46 billion.
  • The interim dividend per share was EU0.85, just shy of the estimated EU0.86.
  • Debt-adjusted cash flow amounted to $7.40 billion, a 13% year-over-year decrease, slightly missing the estimate of $7.46 billion.
  • Cash flow from operations was $12.51 billion, surpassing the estimate by a significant margin, but marked a 23% decrease year-over-year.
  • TotalEnergies reported a daily production of 2.43 million barrels of oil equivalent per day (boe/d), slightly under the estimate of 2.44 million boe/d and down 1.4% from last year.
  • For 2024, the dividend per share was EU3.22, a slight increase from EU3.01 last year but below the estimate of EU3.31.
  • TotalEnergies forecasts first-quarter production for 2025 to be between 2.5 million to 2.55 million boe/d, in line with the estimate of 2.53 million boe/d.
  • For full-year 2025, the company expects hydrocarbon production to grow by more than 3%, aided by the ramp-up of 2024 and new production start-ups.
  • The company projects more than 40 million tonnes of LNG sales in 2025.
  • First-quarter 2025 average LNG selling prices are expected to be above $10 per Mbtu.
  • TotalEnergies anticipates net investments of $17 billion to $17.5 billion for the full year of 2025.
  • The shareholder return policy for 2025 is confirmed, with plans for $2 billion of share buybacks per quarter.

“`


TotalEnergies on Smartkarma

Analysts on Smartkarma have provided varying perspectives on TotalEnergies, a company navigating through changing market conditions. Suhas Reddy‘s Earnings Preview notes TotalEnergies‘ strategy to counter weak oil prices by banking on LNG growth, expecting a drop in Q4 revenue and EPS but gains from higher LNG output and prices. In contrast, Suhas Reddy‘s Earnings Review suggests that TotalEnergies saw a decline in profitability due to sharp refining margin drops in Q3, despite beating revenue forecasts.

Looking ahead, in another Earnings Preview, Suhas Reddy highlights the risks TotalEnergies faces from declining oil prices in Q3 but also the relief from better gas prices, while emphasizing the firm’s long-term growth prospects in LNG and solar energy. These insights offer investors a comprehensive view of TotalEnergies‘ performance and future outlook based on the latest analyst coverage on Smartkarma.


A look at TotalEnergies Smart Scores

FactorScoreMagnitude
Value4
Dividend5
Growth4
Resilience4
Momentum3
OVERALL SMART SCORE4.0

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Based on the Smartkarma Smart Scores, TotalEnergies seems to have a positive long-term outlook. The company scores high in areas like Dividend and Resilience, indicating strong performance in these factors. TotalEnergies‘ stable dividend and ability to withstand market challenges bode well for its future sustainability. With solid scores in Value and Growth as well, the company is positioned for potential growth and value creation over the long haul.

TotalEnergies, formerly known as TOTAL S.A., is engaged in various aspects of the energy sector, including exploration, production, refining, and marketing of oil and natural gas. Additionally, the company has a chemical division that produces a range of products widely used in various industries. Operating gasoline stations across Europe, the United States, and Africa, TotalEnergies has a diversified business portfolio that could contribute to its resilience and growth in the coming years.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars

GlaxoSmithKline PLC (GSK) Earnings: 4Q Adjusted EPS Surpasses Estimates with Robust Revenue Growth

By | Earnings Alerts
“`html

  • GSK reported an adjusted EPS of 23.2p, surpassing the estimate of 20.4p.
  • Total revenue came in at GBP8.12 billion, beating the expected GBP7.9 billion.
  • Specialty Medicines sales totaled GBP3.30 billion, ahead of the GBP3.24 billion estimate.
  • Vaccines sales reached GBP2.21 billion, slightly below the estimate of GBP2.25 billion.
  • General Medicines sales were GBP2.61 billion, exceeding the estimated GBP2.47 billion.
  • Shingrix generated GBP848 million, surpassing its projection of GBP840.8 million.
  • Arexvy revenue fell short at GBP158 million compared to an expected GBP251.6 million.
  • Bexsero revenue was significantly higher at GBP227 million against a forecast of GBP164.2 million.
  • Flixotide/Flovent brought in GBP143 million, outperforming the expected GBP87.7 million.
  • Relvar/Breo Ellipta revenue was slightly below estimate at GBP275 million against GBP282.8 million.
  • Advair/Seretide revenue exceeded expectations at GBP259 million compared to GBP235.5 million.
  • Trelegy Ellipta generated GBP669 million, marginally below the estimate of GBP676.4 million.
  • Xevudy reported GBP11 million against a negative projection of -GBP0.74 million.
  • Triumeq revenue was GBP346 million, surpassing the estimate of GBP337.1 million.
  • Tivicay revenue came in at GBP343 million, beating the projected GBP313 million.
  • Dovato sales totaled GBP638 million, surpassing the GBP597.7 million expectation.
  • Juluca revenue was slightly higher than forecasted at GBP189 million against GBP186.9 million.
  • Nucala generated GBP484 million, underperforming the estimate of GBP516 million.
  • Benlysta revenue was GBP423 million, below the estimated GBP439.5 million.
  • Zejula revenue of GBP143 million was less than the expected GBP161.3 million.
  • The adjusted operating margin stood at 17.6%, slightly below the estimate of 18.2%.
  • R&D expenses were higher than expected at GBP1.82 billion versus GBP1.73 billion.
  • General and administrative expenses were lower than anticipated at GBP2.70 billion against an estimate of GBP2.73 billion.
  • GSK raised its 2031 sales target to over Β£40 billion from the previous target of more than Β£38 billion, adjusted for risk and at CER.
  • The company maintained its 2026 core operating profit margin expectation of more than 31%.
  • Analyst ratings include 8 buys, 13 holds, and 4 sells.

“`


A look at GlaxoSmithKline PLC Smart Scores

FactorScoreMagnitude
Value2
Dividend4
Growth3
Resilience2
Momentum3
OVERALL SMART SCORE2.8

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

GlaxoSmithKline PLC, a research-based pharmaceutical company, has received a mixed bag of SmartKarma Smart Scores for its long-term outlook. With above-average scores in Dividend and Growth, indicating a solid dividend payout and moderate growth potential, the company shows promise in these areas. However, lower scores in Value and Resilience suggest that there may be challenges in terms of undervaluation and resilience to market fluctuations. Momentum, with a mid-range score, hints at a steady but not rapid pace of growth for the company. Overall, while GlaxoSmithKline PLC demonstrates strengths in dividends and growth, there are areas where improvements could bolster its long-term prospects.

GlaxoSmithKline PLC offers a range of products in the pharmaceutical sector, including vaccines, prescription drugs, over-the-counter medicines, and health-related consumer products. The company’s portfolio spans various medical fields, such as infections, depression, skin conditions, asthma, heart and circulatory diseases, and cancer. With a diversified product line catering to different health needs, GlaxoSmithKline PLC plays a significant role in the healthcare industry. The SmartKarma Smart Scores provide valuable insights into different aspects of the company’s performance, highlighting both strengths and areas for potential enhancement in its long-term trajectory.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars

Swedish Orphan Biovitrum AB (SOBI) Earnings: 4Q Revenue Aligned with Estimates at SEK7.44 Billion

By | Earnings Alerts
  • Sobi’s fourth-quarter revenue amounted to SEK 7.44 billion, slightly above the estimate of SEK 7.39 billion.
  • The company’s EBIT (Earnings Before Interest and Taxes) was SEK 1.66 billion, close to the estimate of SEK 1.7 billion.
  • Analysts’ recommendations include 12 buys, 3 holds, and 1 sell.

A look at Swedish Orphan Biovitrum AB Smart Scores

FactorScoreMagnitude
Value3
Dividend1
Growth3
Resilience3
Momentum4
OVERALL SMART SCORE2.8

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Swedish Orphan Biovitrum AB (SOBI) shows promising potential for long-term growth, supported by favorable scores in Growth, Resilience, and Momentum as per Smartkarma Smart Scores. With a solid Growth score of 3, the company is positioned well for expansion in the future. Additionally, a Resilience score of 3 indicates a robust ability to weather challenges, providing stability in the long run. Momentum, with a score of 4, suggests strong market performance and investor interest in SOBI’s offerings.

While the company scores lower in Dividend, with a score of 1, the overall outlook remains positive for Swedish Orphan Biovitrum AB due to its competitive scores in key areas essential for long-term success. As a bio-pharmaceutical and bio-technology firm specializing in therapies for various diseases, including haemophilia and inflammation, SOBI caters to a global clientele, positioning it well for sustained growth and innovation in the pharmaceutical sector.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars

SSE PLC (SSE) Earnings: FY Adjusted EPS Forecasted Between 154p and 163p Amid Strong Renewables Growth

By | Earnings Alerts
“`html

  • SSE expects its full year adjusted earnings per share (EPS) for 2024/25 to be between 154p and 163p.
  • The estimated EPS was initially set at 163p.
  • Renewables output has increased by 26% year-on-year in the first three quarters.
  • This rise in renewables is attributed to capacity additions and varying weather conditions.
  • Operating profit expectations for SSE’s business units remain unchanged.
  • SSE emphasizes its role in the UK’s Clean Power Action Plan by focusing on renewables, networks, and system flexibility.
  • The current analyst recommendations for SSE are comprised of 16 buy ratings, 1 hold, and 0 sells.

“`


A look at SSE PLC Smart Scores

FactorScoreMagnitude
Value3
Dividend4
Growth4
Resilience2
Momentum3
OVERALL SMART SCORE3.2

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

SSE PLC, a company involved in generating, transmitting, and distributing electricity in the UK and Ireland, shows a promising long-term outlook based on Smartkarma Smart Scores. With solid scores in Dividend and Growth factors, SSE PLC is positioned well to provide consistent returns to its shareholders while maintaining a trajectory for expansion and development.

Despite facing challenges in terms of Resilience and Momentum, SSE PLC‘s overall outlook remains positive, indicating a potential for growth and stability in the coming years. With a balanced mix of strengths in different areas, SSE PLC showcases a strategic approach to its operations in the energy sector and related services, demonstrating a foundation for sustained performance and resilience in the market.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars